METHODS FOR ASSESSING CANCER

• US 20140287937A1
• Filed: 02/21/2014
• Published: 09/25/2014
• Est. Priority Date: 02/21/2013
• Status: Abandoned Application

• Current Assignee: Toma Biosciences, Inc. (Trident Labs, Inc.)
• Original Assignee: Toma Biosciences, Inc. (Trident Labs, Inc.)
• Inventors: So, Austin, LUCERO, Michael Y.
• Application Number:
  US14/187,041
• Publication Number:
  US 20140287937A1
• Time in Patent Office: Days
• US Class Current: 506/7
• CPC Class Codes: C12Q 1/6806 Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6855 Ligating adaptors
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

Provided herein are methods for assessing cancer, comprising analysis of sequence data from a set of cancer-related genes in a tumor sample from a subject, followed by monitoring of a subset of the set in circulating tumor-associated DNA in a fluid sample from the subject. Also provided are kits and systems for practicing any of them methods of the invention.

Claims

1. A method of monitoring cancer progression in a subject in need thereof, comprising:

(a) determining the presence, absence, and/or amount of each of a subset of genes in a sample derived from a fluid sample in the subject, wherein the subset is determined by (i) performing targeted sequencing on a set of genes on a solid tissue sample from the subject wherein the solid tissue sample is known or suspected of comprising cancerous tissue;

(ii) determining a profile of genetic mutations for said set of genes based on the sequencing; and

(iii) selecting a subset of 2, 3, or 4 genes of the set of genes based on said profile for said set, wherein said subset is specific to said subject; and

(b) using the results of (a) to monitor progression of the cancer or lack thereof in the subject.

3. The method of claim 1, wherein said set of genes comprises at least 10 genes.

6. The method of claim 1, wherein the set of genes is selected from the group consisting of ABCA1, BRAF, CHD5, EP300, FLT1, ITPA, MYC, PIK3R1, SKP2, TP53, ABCA7, BRCA1, CHEK1, EPHA3, FLT3, JAK1, MYCL1, PIK3R2, SLC19A1, TP73, ABCB1, BRCA2, CHEK2, EPHA5, FLT4, JAK2, MYCN, PKHD1, SLC1A6, TPM3, ABCC2, BRIP1, CLTC, EPHA6, FN1, JAK3, MYH2, PLCB1, SLC22A2, TPMT, ABCC3, BUB1B, COL1A1, EPHA7, FOS, JUN, MYH9, PLCG1, SLCO1B3, TPO, ABCC4, Clorf144, COPS5, EPHA8, FOXO1, KBTBD11, NAV3, PLCG2, SMAD2, TPR, ABCG2, CABLES1, CREB1, EPHB1, FOXO3, KDM6A, NBN, PML, SMAD3, TR10, ABL1, CACNA2D1, CREBBP, EPHB4, FOXP4, KDR, NCOA2, PMS2, SMAD4, TRRAP, ABL2, CAMKV, CRKL, EPHB6, GAB1, KIT, NEK11, PPARG, SMARCA4, TSC1, ACVR1B, CARD11, CRLF2, EPO, GATA1, KLF6, NF1, PPARGC1A, SMARCB1, TSC2, ACVR2A, CARM1, CSF1R, ERBB2, GLI1, KLHDC4, NF2, PPP1R3A, SMO, TTK, ADCY9, CAV1, CSMD3, ERBB3, GLI3, KRAS, NKX2-1, PPP2R1A, SOCS1, TYK2, AGAP2, CBFA2T3, CSNK1G2, ERBB4, GNA11, LMO2, NOS2, PPP2R1B, SOD2, TYMS, AKT1, CBL, CTNNA1, ERCC1, GNAQ, LRP1B, NOS3, PRKAA2, SOS1, UGT1A1, AKT2, CCND1, CTNNA2, ERCC2, GNAS, LRP2, NOTCH1, PRKCA, SOX10, UMPS, AKT3, CCND2, CTNNB1, ERCC3, GPR124, LRP6, NOTCH2, PRKCZ, SOX2, USP9X, ALK, CCND3, CYFIP1, ERCC4, GPR133, LTK, NOTCH3, PRKDC, SP1, VEGF, ANAPC5, CCNE1, CYLD, ERCC5, GRB2, MAN1B1, NPM1, PTCH1, SPRY2, VEGFA, APC, CD40LG, CYP19A1, ERCC6, GSK3B, MAP2K1, NQO1, PTCH2, SRC, VHL, APC2, CD44, CYP1B1, ERG, GSTP1, MAP2K2, NR3Cl, PTEN, ST6GAL2, WRN, AR, CD79A, CYP2C19, ERN2, GUCY1A2, MAP2K4, NRAS, PTGS2, STAT1, WT1, ARAF, CD79B, CYP2C8, ESR1, HDAC1, MAP2K7, NRP2, PTPN11, STAT3, XPA, ARFRP1, CDC42, CYP2D6, ESR2, HDAC2, MAP3K1, NTRK1, PTPRB, STK11, XPC, ARID1A, CDC42BPB, CYP3A4, ETV4, HGF, MAPK1, NTRK2, PTPRD, SUFU, ZFY, ATM, CDC73, CYP3A5, EWSR1, HIF1A, MAPK3, NTRK3, RAD50, SULT1A1, ZNF521, ATP5A1, CDH1, DACH2, EXT1, HM13, MAPK8, OMA1, RAD51, SUZ12, ATR, CDH10, DCC, EZH2, HMGA1, MARK3, OR10R2, RAFT, TAF1, AURKA, CDH2, DCLK3, FANCA, HNF1A, MCL1, PAK3, RARA, TBX22, AURKB, CDH2O, DDB2, FANCD2, HOXA3, MDM2, PARP1, RB1, TCF12, BAI3, CDH5, DDB2, FANCE, HOXA9, MDM4, PAX5, REM1, TCF3, BAP1, CDK2, DGKB, FANCF, HRAS, MECOM, PCDH15, RET, TCF4, BARD1, CDK4, DGKZ, FAS, HSP90AA1, MEN1, PCDH18, RICTOR, TEK, BAX, CDK6, DIRAS3, FBXW7, IDH1, MET, PCNA, RIPK1, TEP1, BCL11A, CDK7, DLG3, FCGR3A, IDH2, MITF, PDGFA, ROR1, TERT, BCL2, CDK8, DLL1, FES, IFNG, MLH1, PDGFB, ROR2, TET2, BCL2A1, CDKN1A, DNMT1, FGFR1, IGF1R, MLL, PDGFRA, ROS1, TGFBR2, BCL2L1, CDKN1B, DNMT3A, FGFR2, IGF2R, MLL3, PDGFRB, RPS6KA2, THBS1, BCL2L2, CDKN2A, DNMT3B, FGFR3, IKBKE, MPL, PDZRN3, RPTOR, TNFAIP3, BCL3, CDKN2B, DOT1L, FGFR4, IKZF1, MRE11A, PHLPP2, RSPO2, TNKS, BCL6, CDKN2C, DPYD, FH, IL2RG, MSH2, PIK3C3, RSPO3, TNKS2, BCR, CDKN2D, E2F1, FHOD3, INHBA, MSH6, PIK3CA, RUNX1, TNNI3K, BIRC5, CDX2, EED, FIGF, INSR, MTHFR, PIK3CB, SDHB, TNR, BIRC6, CEBPA, EGF, FLG2, IRS1, MTOR, PIK3CD, SF3B1, TOP1, BLM, CERK, EGFR, FLNC, IRS2, MUTYH, PIK3CG, SHC1, and TOP2A.

7. The method of claim 1, wherein the fluid sample is selected from the group consisting of blood, serum, plasma, urine, sweat, tears, saliva, or sputum.

8. The method of claim 1, wherein (a) and (b) are performed at a plurality of time points to monitor the status of the cancer over time.

10. The method of claim 1, further comprising generating a report communicating the profile of genetic mutations for the set of genes and communicating said report to a caregiver.

13. The method of claim 10, wherein the report comprises copy number alterations of said set of genes.

16. The method of claim 1, wherein said determining comprises diluting said nucleic acid molecules from said sample into discrete reaction volumes, wherein said discrete reaction volumes contain between 1 to 10 molecules of said nucleic acid molecule from said sample.

17. The method of claim 16, wherein said discrete reaction volumes are droplets in an emulsion.

20. The method of claim 1, wherein the targeted sequencing comprises preparing a DNA library from said solid tissue sample, wherein said preparing does not require exponential PCR amplification prior to sequencing of said library.

23. The method of claim 1, wherein the step of targeted sequencing comprises:

(a) contacting a single-stranded DNA fragment from said solid tissue sample with a target-specific oligonucleotide comprising (i) a region specific for a region of a cancer-related gene and (ii) an adaptor sequence specific for coupling to a sequencing platform;

(b) performing a hybridization reaction to join said target specific oligonucleotides to a single-stranded DNA fragment containing a region of complementarity to said target-specific oligonucleotide;

(c) performing an extension reaction to create an extension product comprising said region and comprising said adaptor; and

(d) sequencing said extension product.

25. The method of claim 23, wherein said contacting occurs with the target-specific oligonucleotide free in a solution.

71. The method of claim 1, wherein the fluid sample is a cell free or substantially cell free genomic sample.

72. The method of claim 1, wherein the monitoring of the cancer progression is used to monitor the efficacy of a cancer treatment.

73. The method of claim 1, wherein the profile of genetic mutations comprises copy number variations.

74. The method of claim 1, wherein the one or more genes comprises TP53.

75. The method of claim 74, wherein the cancer is breast cancer.

2. (canceled)

4. (canceled)

5. (canceled)

9. (canceled)

11. (canceled)

12. (canceled)

14. (canceled)

15. (canceled)

18. (canceled)

19. (canceled)

21. (canceled)

22. (canceled)

24. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30. (canceled)

31. (canceled)

32. (canceled)

33. (canceled)

34. (canceled)

35. (canceled)

36. (canceled)

37. (canceled)

38. (canceled)

39. (canceled)

40. (canceled)

41. (canceled)

42. (canceled)

43. (canceled)

44. (canceled)

45. (canceled)

46. (canceled)

47. (canceled)

48. A method of detecting a mutation in a target polynucleotide region, comprising:

(a) selectively hybridizing an oligonucleotide primer to said target polynucleotide region, wherein said oligonucleotide primer comprises (i) a probe-binding region, and (ii) a template binding region that is at least 70% complementary to a template nucleic acid suspected of harboring a mutation, wherein a portion of said template binding region at least partially overlays a locus of said suspected mutation, and wherein said oligonucleotide primer upon hybridization to said template nucleic acid is extendable by a polymerase if said mutation is present but is not extendable by said polymerase if said mutation is not present;

(b) extending said hybridized oligonucleotide primer to form an extension product; and

(c) detecting said extension product, whereby wherein said detecting indicates the presence of said mutation.

49. The method of claim 48, wherein said extending comprises extending with a DNA polymerase that does not comprise 3′

to 5′

exonuclease activity.

50. The method of claim 48, wherein said detecting comprises selectively hybridizing a reporter probe to said probe binding region.

51. The method of claim 50, wherein said reporter probe comprises a detectable moiety and a quencher moiety, wherein said quencher moiety suppresses detection of said detectable moiety when said reporter probe is intact.

53. The method of claim 50, further comprising amplifying said extension product with a reverse primer that is capable of hybridizing to a region of said extension product downstream of said locus.

54. The method of claim 53, wherein said amplifying comprises amplifying with a DNA polymerase that comprises 5′

to 3′

exonuclease activity.

60. The method of claim 48, wherein said mutation is a single nucleotide polymorphism (SNP).

61. The method of claim 60, wherein said template binding region comprises a 3′

terminal region having a base that overlays said SNP locus.

64. The method of claim 48, wherein said probe-binding region does not hybridize to said target polynucleotide region.

65. The method of claim 48, further comprising subdividing said nucleic acid sample into a plurality of discrete reaction volumes and detecting a presence or absence of said detectable moiety in each of said reaction volumes.

66. The method of claim 65, further comprising counting a number of said reaction volumes wherein said detectable moiety is detected.

78. The method of claim 51, wherein a hybridization product of said oligonucleotide primer and reporter probe has a Tm that is at least 10 degrees higher than a Tm of a hybridization product between said oligonucleotide primer and target polynucleotide.

52. (canceled)

55. (canceled)

56. (canceled)

57. (canceled)

58. (canceled)

59. (canceled)

62. (canceled)

63. (canceled)

67. (canceled)

68. (canceled)

69. (canceled)

70. A method, comprising:

(a) hybridizing a target-selective oligonucleotide (TSO) to a single-stranded DNA (ssDNA) fragment of an ssDNA library to create a hybridization product, wherein the TSO comprises (i) a region sequence that selectively is complementary to a single target genomic region and (ii) a second single-stranded adaptor sequence located at a first end of the TSO, wherein the ssDNA fragment comprises a second adaptor sequence attached to said ssDNA fragment via single-stranded ligation and further wherein said second adaptor sequence is different than said first adaptor sequence; and

(b) amplifying the hybridization product to create a double stranded extension product.

76. A method for assessing status of cancer in a subject, comprising:

(a) obtaining a cell free plasma sample from said subject;

(b) extracting targeted polynucleotides from said sample;

(c) analyzing by digital sequencing said targeted polynucleotides to obtain a genetic profile for a set of genes; and

,

(d) using said genetic profile to assess the status of the cancer in said subject.

77. The method of claim 76, wherein the set of genes is determined by (i) performing targeted sequencing on a plurality of genes using a tissue sample from the subject wherein the tissue sample is known or suspected of comprising cancerous tissue;

(ii) detecting genetic mutations for the plurality of genes based on the sequencing; and

(iii) correlating the genetic mutations to identify the set of genes associated with the cancer in said subject.